Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Insulin glulisine
SANOFI-AVENTIS SINGAPORE PTE. LTD.
A10AB06
3.49 mg (100 Units)
INJECTION, SOLUTION
Insulin glulisine 3.49 mg (100 Units)
SUBCUTANEOUS
Prescription Only
Sanofi-Aventis Deutschland GmbH
ACTIVE
2008-03-20
APIDRA® 100 UNITS/ML SOLUTION FOR INJECTION IN A PRE-FILLED PEN INSULIN GLULISINE SOLOSTAR [SANOFI-AVENTIS LOGO] 1. NAME OF THE MEDICINAL PRODUCT Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 Units insulin glulisine (equivalent to 3.49 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 Units. Insulin glulisine is produced by recombinant DNA technology in _Escherichia coli. _ For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in a pre-filled pen, SoloStar. Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of adults, adolescents and children of 6 years or above with diabetes mellitus, where treatment with insulin is required. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The potency of this preparation is stated in units. These units are exclusive to Apidra and are not the same as IU or the units used to express the potency of other insulin analogues. See section 5.1 (Pharmacodynamics). Apidra should be given shortly (0-15 min) before or soon after meals. Apidra should be used in regimens that include an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemic agents. The dosage of Apidra should be individually adjusted. Administration Apidra should be given by subcutaneous injection or by continuous subcutaneous pump infusion. Apidra should be administered subcutaneously in the abdominal wall, thigh or deltoid or by continuous infusion in the abdominal wall. Injection sites and infusion sites within an injection area (abdomen, thigh or deltoid) should be rotated from one injecti Read the complete document
SG/API/1120/CCDSv12 APIDRA® 100 Units/ml solution for injection in a pre-filled pen Insulin glulisine SoloStar [sanofi logo] 1. NAME OF THE MEDICINAL PRODUCT Apidra SoloStar 100 Units/ml Solution for injection in a pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 Units insulin glulisine (equivalent to 3.49 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 Units. Insulin glulisine is produced by recombinant DNA technology in Escherichia coli. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in a pre-filled pen, SoloStar. Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of adults, adolescents and children of 6 years or above with diabetes mellitus, where treatment with insulin is required. 4.2 Posology and method of administration Posology The potency of this preparation is stated in units. These units are exclusive to Apidra and are not the same as IU or the units used to express the potency of other insulin analogues(see section 5.1). Apidra should be used in regimens that include an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemic agents. The dose of Apidra should be individually adjusted. Method of administration Apidra SoloStar 100 Units/ml in pre-filled pen is only suitable for subcutaneous injections. If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used (see section 4.4). Subcutaneous use Apidra should be given by subcutaneous injection shortly (0-15 min) before or soon after meals or by continuous subcutaneous pump infusion. Apidra should be administered subcutaneously in the abdominal wall, thigh or deltoid or by continuous infusion in the abdominal wall. Injection sites and infusion sites within an injection area (abdomen, thigh or deltoid) should be rotated from one injection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloido Read the complete document